Dose-dense Paclitaxel- and Carboplatin-based Neoadjuvant Chemotherapy Followed by Surgery or Concurrent Chemo-radiotherapy in Cervical Cancer: a Preliminary Analysis

To assess preliminary results with dose-dense neoadjuvant chemotherapy (NACT) prior to surgery or concurrent chemo-radiotherapy (CCRT) in cervical cancer. Thirty patients received weekly paclitaxel (80 mg/m ) plus carboplatin (AUC2) for 6 cycles followed by radical hysterectomy in 16 (stage Ib -IIb)...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 37; no. 3; pp. 1249 - 1255
Main Authors Gadducci, Angiolo, Barsotti, Cecilia, Laliscia, Concetta, Cosio, Stefania, Fanucchi, Antonio, Tana, Roberta, Fabrini, Maria Grazia
Format Journal Article
LanguageEnglish
Published Greece 01.03.2017
Subjects
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carboplatin - administration & dosage
Carcinoma, Squamous Cell - drug therapy
Chemoradiotherapy
Chemotherapy, Adjuvant
Female
Humans
Hysterectomy
Middle Aged
Neoadjuvant Therapy
Neoplasm Recurrence, Local
Paclitaxel - administration & dosage
Remission Induction
Retrospective Studies
Treatment Outcome
Uterine Cervical Neoplasms - drug therapy
Uterine Cervical Neoplasms - radiotherapy
radical hysterectomy
recurrence
paclitaxel
carboplatin
concurrent chemo-radiotherapy
dose-dense neoadjuvant chemotherapy
Cervical cancer
Online AccessGet full text

Cover

More Information
Summary:To assess preliminary results with dose-dense neoadjuvant chemotherapy (NACT) prior to surgery or concurrent chemo-radiotherapy (CCRT) in cervical cancer. Thirty patients received weekly paclitaxel (80 mg/m ) plus carboplatin (AUC2) for 6 cycles followed by radical hysterectomy in 16 (stage Ib -IIb), conisation in one (stage Ib1), and CCRT in 13 (stage Ib -IIb). Median follow-up of survivors was 12 months (range=3-22). Among the surgically treated patients, clinical overall response rate (RR) was 82.3%, optimal pathological RR was 17.6%, and suboptimal pathological RR with intra-cervical residual disease was 41.2%. Only one patient relapsed. Among the CCRT treated patients, partial RR after NACT was 76.9% and complete RR after CCRT was 58.3%. However, 42.8% of complete responders recurred. Toxicity was acceptable. Dose-dense NACT seems to achieve promising RRs with manageable toxicity in cervical cancer. Investigation on larger series with longer follow-up is warranted.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1791-7530